• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of Intracellular Molecularly Targeted Therapy Targeting E7 Protein of HPV that Initiates Cervical Cancer

Research Project

Project/Area Number 17K11301
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Obstetrics and gynecology
Research InstitutionAichi Medical University

Principal Investigator

Yoshikawa Kazuhiro  愛知医科大学, 研究創出支援センター, 特務研究教授 (60109759)

Co-Investigator(Kenkyū-buntansha) 藪下 廣光  愛知医科大学, 医学部, 教授 (00140046)
鈴木 進  愛知医科大学, 加齢医科学研究所, 准教授 (70518422)
Project Period (FY) 2017-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
KeywordsHPV / 抗体 / 免疫治療 / 膜貫通 / cell-penetrating peptide / HPV16-E7 / HPV18-E7 / antibody / scFv / 子宮がん / ペプチド / 子宮頸がん / 組換え型抗体 / HPV-E7 / 細胞膜透過性ペプチド / 子宮頚がん / 組み換え型抗体 / ファージ抗体
Outline of Final Research Achievements

The purpose of this study was to generate antibodies against the E7 gene product of HPV, which is considered to be the cause of cervical cancer, and to apply them to uterine cancer treatment. The gene construction for the antibody-producing phage library was completed. We also attempted to generate mouse monoclonal antibodies by producing antigens with E. coli. However, no antibody that could specifically stain virus-infected cells was obtained. In addition, for the construction of the evaluation system, we screened commercially available antibodies, but were unable to obtain antibodies that could specifically stain viral antigens. Therefore, the desired antibodies could not be obtained.

Academic Significance and Societal Importance of the Research Achievements

本研究は、子宮頸がんの発生原因として考えられているHPVのE7遺伝子産物に対する抗体を作製し、子宮がん治療に応用する事を目的として実施した。HPV16、18の感染が認められた子宮がん患者より採取されたリンパ節細胞から抗体産生ファージライブラリー作成のための遺伝子構築ができたことから、子宮がんだけでなく、その他のがんにおいても同様の抗体作成のためのライブラリー作成の可能性が示された。このことは、それらのライブラリーのスクリーニングより、がん治療用の抗体を得る可能性が示されたということも意義として大きく、今後も研究を続けていく意味のある事と思われた。

Report

(7 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (19 results)

All 2023 2022 2020 2019 2018 2017

All Journal Article (12 results) (of which Int'l Joint Research: 4 results,  Peer Reviewed: 12 results,  Open Access: 7 results) Presentation (6 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens2023

    • Author(s)
      Yamanaka S, Suzuki S, Ito H, Sivasundaram K, Hanamura I, Okubo I, Yoshikawa K, Ono S, Takahara T, Satou A, Tsuzuki T, Ueda R, Ogawa T, Fujimoto Y.
    • Journal Title

      International journal of molecular sciences

      Volume: 24 Issue: 2 Pages: 1722-1722

    • DOI

      10.3390/ijms24021722

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma2022

    • Author(s)
      Ono S, Suzuki S, Kondo Y, Okubo I, Goto M, Ogawa T, Kato H, Ito H, Takahara T, Satou A, Tsuzuki T, Yoshikawa K, Nagao T, Ueda R.
    • Journal Title

      Scientific Reports

      Volume: 12 Issue: 1 Pages: 21678-21678

    • DOI

      10.1038/s41598-022-22773-1

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line.2022

    • Author(s)
      Sakuma K, Kii T, Takahashi H, Suzuki S, Yoshikawa K, Ogawa T, Tanaka A.
    • Journal Title

      Ainticancer Research

      Volume: 42 Issue: 9 Pages: 4293-4303

    • DOI

      10.21873/anticanres.15929

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Immune-checkpoint molecules on regulatory T-cells as potential therapeutic target in head and neck squamous cell cancers.2020

    • Author(s)
      Suzuki S, Ogawa T, Sano R, Takahara T, Inukai D, Satou A, Tsuchida H, Yoshikawa K, Ueda R, Tsuzuki T
    • Journal Title

      Cancer Sci.

      Volume: in press Issue: 6 Pages: 1943-1957

    • DOI

      10.1111/cas.14422

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Combining T‐cell‐based immunotherapy with venetoclax elicits synergistic cytotoxicity to B‐cell lines in vitro2020

    • Author(s)
      Murakami Satsuki、Suzuki Susumu、Hanamura Ichiro、Yoshikawa Kazuhiro、Ueda Ryuzo、Seto Masao、Takami Akiyoshi
    • Journal Title

      Hematological Oncology

      Volume: 38 Issue: 5 Pages: 705-714

    • DOI

      10.1002/hon.2794

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.2019

    • Author(s)
      Watanabe M, Kanao K, Suzuki S, Muramatsu H, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Kato Y, Zennami K, Nakamura K, Tsuzuki T, Yoshikawa K, Ueda R, Sumitomo M.
    • Journal Title

      Prostate

      Volume: 79(14) Issue: 14 Pages: 1658-1665

    • DOI

      10.1002/pros.23890

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] CCR4 expression in tumor-infiltrating regulatory T cells in patients with squamous cell carcinoma of the lung: A prognostic factor for relapse and survival2019

    • Author(s)
      Kubo A, Asai N, Suzuki S, Murotani K, Numanami H, Yoshikawa K, Ueda R, Yamaguchi E
    • Journal Title

      Cancer Invest

      Volume: 37 Issue: 3 Pages: 163-73

    • DOI

      10.1080/07357907.2019.1582848

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Targeting lactate dehydrogenase-A promotes docetaxe-induced cytotoxicity predominantly in castration-resistant prostate cancer cells.2019

    • Author(s)
      Muramatsu H, Sumitomo M, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Kato Y, Watanabe M, Zennami K, Kanao K, Nakamura K, Suzuki S, Yoshikawa K.
    • Journal Title

      Oncol Rep.

      Volume: 42(1) Pages: 224-230

    • DOI

      10.3892/or.2019.7171

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] HOXA10 expression profiling in prostate cancer2019

    • Author(s)
      Hatanaka Yuji、de Velasco Marco A.、Oki Takashi、Shimizu Nobutaka、Nozawa Masahiro、Yoshimura Kazuhiro、Yoshikawa Kazuhiro、Nishio Kazuto、Uemura Hirotsugu
    • Journal Title

      The Prostate

      Volume: 79 Issue: 5 Pages: 554-563

    • DOI

      10.1002/pros.23761

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Systemic transduction of p16INK4a antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice2018

    • Author(s)
      Shimazui Toru、Yoshikawa Kazuhiro、Ishitsuka Ryutaro、Kojima Takahiro、Kandori Shuya、Yoshino Takayuki、Miyazaki Jun、Uchida Kazuhiko、Nishiyama Hiroyuki
    • Journal Title

      Oncology Letters

      Volume: 17 Pages: 1203-1210

    • DOI

      10.3892/ol.2018.9655

    • NAID

      120007128291

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Generation of PTEN?knockout (-/-) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling2018

    • Author(s)
      Takao Akiko、Yoshikawa Kazuhiro、Karnan Sivasundaram、Ota Akinobu、Uemura Hirotsugu、De Velasco Marco、Kura Yurie、Suzuki Susumu、Ueda Ryuzo、Nishino Tokiko、Hosokawa Yoshitaka
    • Journal Title

      Oncology Reports

      Volume: 40 Pages: 2455-2466

    • DOI

      10.3892/or.2018.6683

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study2017

    • Author(s)
      Nishio-Nagai Mayako、Suzuki Susumu、Yoshikawa Kazuhiro、Ueda Ryuzo、Kazaoka Yoshiaki
    • Journal Title

      International Journal of Oncology

      Volume: 51 Issue: 5 Pages: 1471-1481

    • DOI

      10.3892/ijo.2017.4142

    • Related Report
      2017 Research-status Report
    • Peer Reviewed
  • [Presentation] Transforming growth factor-beta inhibitor is a candidate drug for immunotherapy of oral squamous cell carcinoma2022

    • Author(s)
      Yutaro Kondo, Taishi Takahara, Shoya Ono, Mitsuo Goto, Tetsuya Ogawa, Hideaki Ito, Akira Sato, Toyonori Tsuzuki, Kazuhiro Yoshikawa, Ryuzo Ueda, Susumu Suzuki
    • Organizer
      日本癌学会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Establishment passive culture cells derived from mucoepidermoid carcinoma2022

    • Author(s)
      Shunpei Yamanaka, Susumu Suzuki, Hideaki Ito, Shoya Ono, Yutaro Kondo, Daisuke Inukai, Hiroki Okamoto, Taishi Takahara, Toyonori Tsuzuki, Kazuhiro Yoshikawa, Ryuzo Ueda, Tetsuya Ogawa
    • Organizer
      日本癌学会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Characterization of immune-suppressive microenvironment in head & neck cancer2018

    • Author(s)
      佐野 塁,鈴木 進, 小川 徹也, 犬飼 大輔, 岡本 啓希, 高原 大志, 佐藤 啓, 吉川 和宏, 都築 豊徳, 上田 龍三
    • Organizer
      日本癌学会
    • Related Report
      2018 Research-status Report
  • [Presentation] Interrogating genetically engineered mouse models of prostate cancer to aid in immunotherapy development2018

    • Author(s)
      デベラスコ・マルコ, 倉 由吏恵, 森 康範, 清水 信貴, 大關 孝之, 坂井 和子, 野澤 昌弘, 吉村 一宏, 吉川 和宏, 西尾 和人, 植村 天受
    • Organizer
      日本癌学会
    • Related Report
      2018 Research-status Report
  • [Presentation] 頭頸部がん外科免疫治療の開発 手術検体を用いた腫瘍局所における免疫関連細胞・分子の解析から考える2018

    • Author(s)
      小川 徹也, 犬飼 大輔, 岡本 啓希, 山中 俊平, 佐野 塁, 植田 広海, 都築 豊徳, 鈴木 進, 吉川 和宏, 上田 龍三
    • Organizer
      日本頭頸部癌学会
    • Related Report
      2018 Research-status Report
  • [Presentation] 頭頸部がん手術検体を用いたeffector Tregの腫瘍内発現の解析2017

    • Author(s)
      鈴木 進, 西村 邦宏, 小川 徹也, 都築 豊徳, 吉川 和宏, 上田 龍三
    • Organizer
      日本癌学会
    • Related Report
      2017 Research-status Report
  • [Patent(Industrial Property Rights)] エフェクター制御性T細胞の検出と調整2018

    • Inventor(s)
      鈴木進、吉川和宏
    • Industrial Property Rights Holder
      愛知医科大学
    • Industrial Property Rights Type
      特許
    • Filing Date
      2018
    • Acquisition Date
      2022
    • Related Report
      2021 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2024-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi